Business · 10/12/2015Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ELIQUIS Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of ELIQUIS, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →